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the disease1,2. Until now, there is no proven effective
therapy for this disease3. A subgroup of patients has a
rapidly progressive disease or is refractory to conven-
tional treatment and these patients can benefit from in-
tensive immunosuppression and rescue with Autolo-
gous Hematopoietic Stem Cell Transplant (AHSCT).
The justification for the AHSCT was validated by stu-
dies in animal models of autoimmunity and later in
phase I/II/III studies in the framework of the European
Bone Marrow Transplantation (EBMT)6,7.
clInIcAl cAse
Young female, 19 y.o., with SSc difuse subtype, diagno -
sed at 13 y.o., with cutaneous, vascular and articular
involvement. She had severe Raynaud’s phenomenon
since 11 y,o and, at diagnosis, presented with digital
ulcers, skin thickening (modified Rodnan skin score
17,5) and elbow and knee contractures. Nailfold ca-
pillaroscopy showed a scleroderma pattern and she had
positive antinuclear antibodies (1:1280, nucleolar stai-
ning pattern) and anti-Ro 52. Skin thickness and joint
contractures improved with methotrexate but inter-
mittent infusions of iloprost and administration of en-
dothelin receptor antagonist (bosentan) were needed
due to the very painful digital ulcers. Three years after
diagnosis she started severe complaints of gastrointes-
tinal reflux, dyspepsia and dysphagia. Gastrointestinal
endoscopy showed chronic gastritis and esophagitis;
esophageal manometry revealed a lower esophageal
sphincter pressure and weak pressure waves (1/3 lo-
wer esophagus hypo-contractility) in the smooth mus-
cle. Gastric scintigraphy showed 26% emptying at 2
hours. There was no improvement with medication (es-
zomeprazol, domperidona, eritromycine erythromycin
and even cisapride) and there was progression of the di-
sease progressed. Therefore, cyclophosphamide (Cy)
and intravenous IV immunoglobulin had been tried for
3 months. There was an initial mild relieving of the
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AbstrAct
Systemic Sclerosis (SSc) is a chronic disease of the con-
nective tissue, whose pathogenesis involves abnormalities
of the immunological system. It has a variable course and
there is a subgroup of patients with rapidly progressive di-
sease or unresponsive to conventional treatment. These
patients can benefit from intensive immunosuppression
and autologous hematopoietic stem cell transplant.
Clinical case: 19-year-old (y.o.) woman diagnosed with
SSc at the age of 13 y.o. with cutaneous, vascular and ar-
ticular involvement with initial response to me thotrexate.
Three years later the disease progressed with severe di-
gestive involvement (dysphagia, delayed gastric emptying
and weight loss) needing gastrostomy for nutritional sup-
port. She was treated with cyclophosphamide without
improvement. In May 2012 she had an autologous trans-
plant with myeloablative regimen (BEAM): carmustine
300 mg/m2 x1day; etoposide 120 mg/kg x4days; cytara-
bine 120 mg/kg 12/12:h x4days; melphalan 140 mg/m2
x1day. A year and a half after transplantation she is
asympto matic, without any signs or symptoms of the di-
sease, feeds by mouth and the gastric emptying study is
normal. Currently she is free of medication.
Keywords: Systemic sclerosis; Autologous Hemato-
poietic Stem Cell Transplant;
IntroductIon 
Systemic sclerosis (SSc) is a progressive disease, who-
se pathogenesis includes early immunological events
and vascular alterations, especially at the beginning of
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dIscussIon
This case reports the first AHSCT performed for an au-
toimmune disease in Portugal. We would like to em -
phasize the sequential therapy approach with cyclo -
phosphamide in intermediate dose followed by mye-
loablative/immunoablative BEAM therapy and autolo-
gous hematopoietic rescue, considering their possible
synergistic effect. The choice of mobilization regimen
was Chemotherapy (Cy) with G-CSF because priming
chemotherapy is recommended to enhance mobiliza-
tion while maintaining disease control and preventing
potential flare, which could be a consequence of 
G-CSF alone6. The subsequent condition regimen
(BEAM) seemed the best option in this patient, not
only because she didn’t have evidence of pulmonary
damage (and therefore we prevented BCNU toxicity)
but also because its is known that the conditioning re-
gimen be of “intermediate intensity” is associated with
a low transplant rate mortality. Other options such as
"high intensity" conditioning regimens (including to-
tal body irradiation TBI or high-dose regimens
contain ing busulphan) or even "low-intensity" condi-
tioning (referring to cyclophosphamide alone, mel -
phalan alone and fludarabine-based regimens) were
associated with poor improved outcomes when com-
pared with to "intermediate intensity" conditioning re-
gimens like BEAM6,7.
In autoimmune disorders, the reconstituted immu-
ne system following myeloablation/lymphoablation
and autologous transplant yields qualitative changes
in immune defects and modifications in adaptive im-
mune responses. A large worldwide cohort showed
that AHSCT can induce sustained remissions for more
than 5 years in patients with severe autoimmune di-
symptoms and of the gastric emptying in the scinti-
graphy (53% at two hours), but dysphagia and dys-
pepsia remained a major concern. The symptoms pro-
gressed and she became intolerant to solid foods, with
subsequent relevant weight loss and needed gastros-
tomy for nutritional support.
Due to the severity of the disease without response to
conventional therapy and the poor quality of life she was
proposed for AHSCT. On January of 2012 she was trea-
ted with intermediate dose of immunosuppressive the-
rapy (cyclophosphamide (Cy) 4 gr with uromitexan
(Mesna) and cautious hyperhydratation) followed by he-
matopoietic growth factors (G-CSF) for mobilization and
collection of peripheral stem cells progenitors. [Table I].
On May 2012 she had an AHSCT with myeloabla-
tive BEAM regimen (carmustine 300 mg/m2 x1day;
etoposide 120 mg/kg x4days; cytarabine 120 mg/kg
12/12:h x4days; melphalan 140 mg/m2 x1day)4,5 [Ta-
ble – II] and infusion of unmanipulated blood stem
cells (CD34 + = 2.7 x106/kg). She had expected com-
plications after bone marrow transplantation: a grade
3 mucositis with the need of opioid analgesia and to-
tal parenteral nutrition for 5 days; a cutaneous herpes
zoster and a febrile syndrome without clinical focus of
infection and no isolated agent. Hematopoietic reco-
very was as on day +10 for PMN > 500/mm3 and at day
+ 11 for platelets > 20000/mm3. Hospital discharge day
was at day +17 post transplant. Immediately after dis-
charge, the patient had good oral food tolerance (wi -
thout the need for nutritional supplementation by gas-
trostomy) and cutaneous and vascular improvement.
A year and a half after autologous transplantation
the patient is completely assymptomatic, without any
clinical evidence of the disease. She had never had Ray-
naud’s and the gastric emptying and motility are nor-
mal and she has already withdrawn the gastrostomy.
Currently the patient is free of medication.
tAble I. mobIlIzAtIon PHsc regImen 
R
Cy x x
G-CSF x x x Peripheral CD34+ 
cells>10x106/kg
PHSC
Cy: Cyclophosphamide 2 g x 2d + G-CSF: Hematopoietic grow
factors 10mcg/Kg/d); R: recovery; PHSC: peripheral hematopoietic
stem cell
tAble II. condItIonIng regImen (beAm) 
-6 -5 -4 -3 -2 -1 0
BCNU x
VP-16 x x x x
ARA-C x x x x
x x x x
Melph x
BMT
BCNU-300mg/m2x1d; VP-16-200 mg/m2 x4d; ARA-C-200 mg/m2
12/12 h x4d; Melphalan 140 mg/m2 x1d
BMT: bone marrow transplant
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seases refractory to conventional therapy. The type of
autoimmune disease, rather than transplant technique,
was the most relevant determinant of outcome. Results
improved with time and were associated with the trans-
plant centers experience. Early identification of patients
with autoimmune diseases unresponsive to conventio-
nal therapy is extremely important in order to provide
timely eligibility criteria. Ongoing studies aim to use re-
cently published clinical guidelines protocols of the
EBMT, with centralized data collection6,7. Recently, it
was presented the analysis of the (European ASTIS-
-trial), the first international, investigator-initiated,
phase III HSCT trial in early diffuse cutaneous SSc. The
data shows that, despite 10% treatment-related morta-
lity, long term event-free survival and overall survival
were better in the AHSCT group than in the group trea-
ted with intravenous pulse cyclophosphamide8.
With this case the authors would like to emphasize
the use of AHSCT as a valid and successful treatment
for refractory autoimmune diseases, and the impor-
tance of a timely referral. 
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